Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
Sponsor: Sarfez Pharmaceuticals, Inc.
Summary
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
Official title: An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide
Key Details
Gender
MALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2021-06-30
Completion Date
2022-06-30
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
CHF Patients: ER Torsemide 40 mg
ER Torsemide 40mg given once daily to CHF patients
CHF Patients: Furosemide 40 mg
Stable CHF patients taking twice-daily 40 mg Furosemide
Locations (1)
Syngene International
Bangalore, Karnataka, India